The Venture Codex Logo

The Venture Codex

MEDIPAL HOLDINGS CORPORATION

3-1-1 Kyobashi, Chuo-ku, Tokyo, 104-8461, Japan

Overview

Holding company selling pharmaceuticals, cosmetics, and daily necessities.

Founded

1898

Deals · 12mo

2

Links

WebsiteLinkedIn

Stage focus

Multi-stage

Geographic focus

Belgium
Japan

Sector focus

Cosmetics
Pharmaceutical

Investment portfolio

4rounds
NAMEDATESIZE
mutex
Oct 2026Participated
$2 MSeries A
Metagen Therapeutics
Feb 2026Participated
$8 MSeries B
Heartseed
Jun 2021Participated
$37 MSeries C
Promethera Biosciences
May 2019Participated
$45 MSeries D
mutex
Oct 2026Participated
$2 MSeries A
Metagen Therapeutics
Feb 2026Participated
$8 MSeries B
Heartseed
Jun 2021Participated
$37 MSeries C
Promethera Biosciences
May 2019Participated
$45 MSeries D
4
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

MEDIPAL HOLDINGS CORPORATION: 4 funding rounds are recorded in the selected participation categories.All available history.
MEDIPAL HOLDINGS CORPORATION: 4 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01
Series B01
Series C+02

Monthly Deal Activity

MEDIPAL HOLDINGS CORPORATION: 4 deals are recorded across 90 months.All available history.
MEDIPAL HOLDINGS CORPORATION: 4 deals are recorded across 90 months. All available history
MonthDeals
May '191
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '211
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '261
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '261

Sector Breakdown

MEDIPAL HOLDINGS CORPORATION: Health & Life Sciences is the largest displayed sector by deal count (3 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

MEDIPAL HOLDINGS CORPORATION: Health & Life Sciences is the largest displayed sector by deal count (3 deals). All available history
SectorDeals
Health & Life Sciences3
Hardware & Robotics1
Enterprise Software1
AI & Machine Learning1
Space & Frontier Tech1
Consumer & Lifestyle1

Deal Size Distribution

MEDIPAL HOLDINGS CORPORATION: 4 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

MEDIPAL HOLDINGS CORPORATION: 4 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M1
$5M-$10M1
$10M-$25M0
$25M-$50M2
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

MEDIPAL HOLDINGS CORPORATION: Japan has the largest recorded deal count among the displayed regions (3 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

MEDIPAL HOLDINGS CORPORATION: Japan has the largest recorded deal count among the displayed regions (3 deals). All available history
RegionDeals
Japan3
Europe1
MEDIPAL HOLDINGS CORPORATION: 20 co-investors are shown, with ASKA Pharmaceutical sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

MEDIPAL HOLDINGS CORPORATION: 20 co-investors are shown, with ASKA Pharmaceutical sharing 1 recorded deals. All available history
Co-investorShared deals
ASKA Pharmaceutical1
Canon Marketing Japan1
Ci:z Investment1
Itochu Chemical Frontier1
ITOCHU Corporation1
Keio Innovation Initiative1
Korea Investment Partners1
Medical Incubator Japan1
Mirae Asset Capital1
Mitsui & Co. Global Investment1
MTI1
Nippon Management1
Nippon Venture Capital1
Nissay Capital1
SBI Group1
Shinsei Capital Partners1
Six Snow1
SMBC Capital1
Sumitomo Mitsui Trust Investment1
UTokyo Innovation Platform1

Investment Strategy

MEDIPAL HOLDINGS CORPORATION: Led accounts for 0% and participating for 100% of round participation.All available history.
MEDIPAL HOLDINGS CORPORATION: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating4100%
MEDIPAL HOLDINGS CORPORATION: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
MEDIPAL HOLDINGS CORPORATION: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Kazuo Hashida

Executive Officer, Director of Finance & Accounting

Shuichi Watanabe

Representative Director, President and CEO

Toshihide Yoda

Director